Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determinate the free-progression interval in patients with
surgically resected locally advanced squamous cell carcinoma of head and neck treated with
the maximum tolerated dose of the combination of erlotinib, radiation therapy and cisplatin,
previously established in a safety trial.
Phase:
Phase 3
Details
Lead Sponsor:
Grupo de Investigación Clínica en Oncología Radioterapia